Click here to get full coverage on Only FDA-approved post-surgery nausea drug shifts to new owner - Stock Titan

Only FDA-approved post-surgery nausea drug shifts to new owner  Stock Titan

Only FDA-approved post-surgery nausea drug shifts to new owner - Stock Titan

Click here to get full coverage on Eagle Pharmaceuticals Announces Divestiture Of Barhemsys - TradingView — Track All Markets

Eagle Pharmaceuticals Announces Divestiture Of Barhemsys  TradingView — Track All Markets

Eagle Pharmaceuticals Announces Divestiture Of Barhemsys - TradingView — Track All Markets

Click here to get full coverage on Eagle Pharmaceuticals Announces Divestiture of Barhemsys - The Manila Times

Eagle Pharmaceuticals Announces Divestiture of Barhemsys  The Manila Times

Eagle Pharmaceuticals Announces Divestiture of Barhemsys - The Manila Times

Click here to get full coverage on Eagle Pharma (OTCMKTS: EGRX) extends stockholder rights plan to 2026; $20 exercise - Stock Titan

Eagle Pharma (OTCMKTS: EGRX) extends stockholder rights plan to 2026; $20 exercise  Stock Titan

Eagle Pharma (OTCMKTS: EGRX) extends stockholder rights plan to 2026; $20 exercise - Stock Titan

Click here to get full coverage on Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan - Yahoo Finance

Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan  Yahoo Finance

Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan - Yahoo Finance

Click here to get full coverage on Annual Meeting Alert: Eagle Pharmaceuticals Releases Two Years of Audited Financials Ahead of October Meeting - Stock Titan

Annual Meeting Alert: Eagle Pharmaceuticals Releases Two Years of Audited Financials Ahead of October Meeting  Stock Titan

Annual Meeting Alert: Eagle Pharmaceuticals Releases Two Years of Audited Financials Ahead of October Meeting - Stock Titan

Click here to get full coverage on Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly - GlobeNewswire

Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly  GlobeNewswire

Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly - GlobeNewswire

Click here to get full coverage on Eagle Pharmaceuticals, inc (EGRX) Q3 2021 Earnings Call Transcript - The Motley Fool

Eagle Pharmaceuticals, inc (EGRX) Q3 2021 Earnings Call Transcript  The Motley Fool

Eagle Pharmaceuticals, inc (EGRX) Q3 2021 Earnings Call Transcript - The Motley Fool

Click here to get full coverage on Q1 2025 Unaudited Financials — Eagle Pharmaceuticals posts statements and investor materials available now - Stock Titan

Q1 2025 Unaudited Financials — Eagle Pharmaceuticals posts statements and investor materials available now  Stock Titan

Q1 2025 Unaudited Financials — Eagle Pharmaceuticals posts statements and investor materials available now - Stock Titan

Click here to get full coverage on Eagle Pharmaceuticals to Delist from Nasdaq - Investing.com

Eagle Pharmaceuticals to Delist from Nasdaq  Investing.com

Eagle Pharmaceuticals to Delist from Nasdaq - Investing.com

Click here to get full coverage on Eagle Pharmaceuticals and Acacia Pharma Transaction - William Blair

Eagle Pharmaceuticals and Acacia Pharma Transaction  William Blair

Eagle Pharmaceuticals and Acacia Pharma Transaction - William Blair

Click here to get full coverage on Does Eagle Pharmaceuticals (NASDAQ:EGRX) Have A Healthy Balance Sheet? - Yahoo Finance

Does Eagle Pharmaceuticals (NASDAQ:EGRX) Have A Healthy Balance Sheet?  Yahoo Finance

Does Eagle Pharmaceuticals (NASDAQ:EGRX) Have A Healthy Balance Sheet? - Yahoo Finance

Click here to get full coverage on ROSEN, LEADING INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX - FinancialContent

ROSEN, LEADING INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX  FinancialContent

ROSEN, LEADING INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX - FinancialContent

Click here to get full coverage on Major Cash Injection: Eagle Pharma Lands $69M Through Strategic Royalty Sale - Stock Titan

Major Cash Injection: Eagle Pharma Lands $69M Through Strategic Royalty Sale  Stock Titan

Major Cash Injection: Eagle Pharma Lands $69M Through Strategic Royalty Sale - Stock Titan

Click here to get full coverage on Eagle Pharmaceuticals (EGRX) Shares Crash After CEO Tarriff - GlobeNewswire

Eagle Pharmaceuticals (EGRX) Shares Crash After CEO Tarriff  GlobeNewswire

Eagle Pharmaceuticals (EGRX) Shares Crash After CEO Tarriff - GlobeNewswire

Click here to get full coverage on DEADLINE ALERT for GM, EGRX, MRCY, and ON: The Law Offices - GlobeNewswire

DEADLINE ALERT for GM, EGRX, MRCY, and ON: The Law Offices  GlobeNewswire

DEADLINE ALERT for GM, EGRX, MRCY, and ON: The Law Offices - GlobeNewswire

Click here to get full coverage on Eagle Pharmaceuticals to Complete Nasdaq Delisting After Trading Suspension - Stock Titan

Eagle Pharmaceuticals to Complete Nasdaq Delisting After Trading Suspension  Stock Titan

Eagle Pharmaceuticals to Complete Nasdaq Delisting After Trading Suspension - Stock Titan

Click here to get full coverage on Eagle Pharmaceuticals (EGRX) Stock Price, News & Analysis - MarketBeat

Eagle Pharmaceuticals (EGRX) Stock Price, News & Analysis  MarketBeat

Eagle Pharmaceuticals (EGRX) Stock Price, News & Analysis - MarketBeat

Click here to get full coverage on Redlands Daily Facts - FinancialContent

Redlands Daily Facts - FinancialContent

Click here to get full coverage on PRN_FinancialWrapper - FinancialContent

PRN_FinancialWrapper - FinancialContent

Click here to get full coverage on Aadi Bioscience (NASDAQ:AADI) vs. Eagle Pharmaceuticals (NASDAQ:EGRX) Head to Head Survey - Defense World

Aadi Bioscience (NASDAQ:AADI) vs. Eagle Pharmaceuticals (NASDAQ:EGRX) Head to Head Survey  Defense World

EGRX

Price Chart

Key Statistics

Technicals

About EGRX

Latest News

Only FDA-approved post-surgery nausea drug shifts to new owner - Stock Titan

Eagle Pharmaceuticals Announces Divestiture Of Barhemsys - TradingView — Track All Markets

Eagle Pharmaceuticals Announces Divestiture of Barhemsys - The Manila Times

Advanced Charts

Top Gainers

Top Losers